Jewish Press3h
Targeted mRNA Therapy Holds Promise for Crohn’s Disease, Colitis, and Beyond
The findings suggest that lipid composition can direct mRNA-based drugs to target organs, such as the intestines, without passing through the liver.
Ibj.com2h
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...
Pharm Exec5h
Treating Disruptive Symptom’s in Crohn’s Patients: Q&A with Mark Genovese, MD
Mark Genovese: Crohn’s disease is a chronic, inflammatory bowel disease associated with progressive bowel damage, disability, ...
Turkey tail: can it really support cancer treatment?
This functional mushroom has experts buzzing for its potential effects on weight loss, mental health, and even as an ...
F.D.A. Approves Ozempic to Treat Kidney Disease
The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...
Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...
Pain medication finds new purpose fighting toxins from kidney disease
Mefenamic acid, a common anti-inflammatory drug already approved for pain management, has been found to significantly reduce ...
Novo’s Ozempic Notches Approval for Kidney Disease, Widening Use
Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 ...
The Lancet16h
Weight-loss medications: promoting health and not harm
In 2023, the American Academy of Pediatrics published a clinical practice guideline recommending weight-loss medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, as a supplement ...